225 related articles for article (PubMed ID: 26782932)
21. miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Zhang M; Piao L; Datta J; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
Mol Cancer Ther; 2015 Oct; 14(10):2313-20. PubMed ID: 26227488
[TBL] [Abstract][Full Text] [Related]
22. Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.
Stein AP; Swick AD; Smith MA; Blitzer GC; Yang RZ; Saha S; Harari PM; Lambert PF; Liu CZ; Kimple RJ
Cancer Med; 2015 May; 4(5):699-712. PubMed ID: 25619980
[TBL] [Abstract][Full Text] [Related]
23. CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.
Alama A; Gangemi R; Ferrini S; Barisione G; Orengo AM; Truini M; Bello MG; Grossi F
Arch Immunol Ther Exp (Warsz); 2015 Jun; 63(3):207-14. PubMed ID: 25678473
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
26. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
Martinez-Useros J; Garcia-Foncillas J
Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
[TBL] [Abstract][Full Text] [Related]
27. Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer.
Hartmann S; Zwick L; Maurus K; Fuchs AR; Brands RC; Seher A; Kübler AC; Müller-Richter UDA
J Craniomaxillofac Surg; 2018 Mar; 46(3):492-497. PubMed ID: 29311018
[TBL] [Abstract][Full Text] [Related]
28. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
29. Afatinib and lung cancer.
Jain P; Khanal R; Sharma A; Yan F; Sharma N
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
[TBL] [Abstract][Full Text] [Related]
30. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
31. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
Price KA; Cohen EE
Oral Oncol; 2015 May; 51(5):399-408. PubMed ID: 25725588
[TBL] [Abstract][Full Text] [Related]
33. Clinical perspective of afatinib in non-small cell lung cancer.
Chen X; Zhu Q; Zhu L; Pei D; Liu Y; Yin Y; Schuler M; Shu Y
Lung Cancer; 2013 Aug; 81(2):155-61. PubMed ID: 23664448
[TBL] [Abstract][Full Text] [Related]
34. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.
Abhold EL; Kiang A; Rahimy E; Kuo SZ; Wang-Rodriguez J; Lopez JP; Blair KJ; Yu MA; Haas M; Brumund KT; Altuna X; Patel A; Weisman RA; Ongkeko WM
PLoS One; 2012; 7(2):e32459. PubMed ID: 22384257
[TBL] [Abstract][Full Text] [Related]
35. Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma.
Longton E; Schmit K; Fransolet M; Clement F; Michiels C
Front Oncol; 2018; 8():432. PubMed ID: 30345256
[TBL] [Abstract][Full Text] [Related]
36. Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.
Watanuki Z; Kosai H; Osanai N; Ogama N; Mochizuki M; Tamai K; Yamaguchi K; Satoh K; Fukuhara T; Maemondo M; Ichinose M; Nukiwa T; Tanaka N
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):269-76. PubMed ID: 25446083
[TBL] [Abstract][Full Text] [Related]
37. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
[TBL] [Abstract][Full Text] [Related]
39. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
40. Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.
Hartmann S; Neckel N; Seher A; Mutzbauer G; Brands RC; Linz C; Kübler AC; Müller-Richter UD
Clin Oral Investig; 2016 May; 20(4):759-69. PubMed ID: 26297130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]